280 related articles for article (PubMed ID: 34286886)
1. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.
Wu LT; John WS; Morse ED; Adkins S; Pippin J; Brooner RK; Schwartz RP
Addiction; 2022 Feb; 117(2):444-456. PubMed ID: 34286886
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network.
Wu LT; John WS; Ghitza UE; Wahle A; Matthews AG; Lewis M; Hart B; Hubbard Z; Bowlby LA; Greenblatt LH; Mannelli P;
Addiction; 2021 Jul; 116(7):1805-1816. PubMed ID: 33428284
[TBL] [Abstract][Full Text] [Related]
3. Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff.
Wu LT; Mannelli P; John WS; Anderson A; Schwartz RP
Subst Abuse Treat Prev Policy; 2023 Sep; 18(1):55. PubMed ID: 37697326
[TBL] [Abstract][Full Text] [Related]
4. Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S.
Wu LT; John WS; Mannelli P; Morse ED; Anderson A; Schwartz RP
Addict Sci Clin Pract; 2023 Aug; 18(1):45. PubMed ID: 37533071
[TBL] [Abstract][Full Text] [Related]
5. Opioid treatment program prescribing of methadone with community pharmacy dispensing: Pilot study of feasibility and acceptability.
Brooner RK; Stoller KB; Patel P; Wu LT; Yan H; Kidorf M
Drug Alcohol Depend Rep; 2022 Jun; 3():. PubMed ID: 35757566
[TBL] [Abstract][Full Text] [Related]
6. Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies.
Gauthier G; Eibl JK; Marsh DC
Drug Alcohol Depend; 2018 Oct; 191():1-5. PubMed ID: 30064001
[TBL] [Abstract][Full Text] [Related]
7. Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic.
López-Castro T; Jakubowski A; Masyukova M; Peterson M; Pierz A; Kodali S; Arnsten JH; Starrels JL; Nahvi S
J Subst Use Addict Treat; 2024 Feb; 157():209235. PubMed ID: 38061636
[TBL] [Abstract][Full Text] [Related]
8. Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care.
Taylor JL; Laks J; Christine PJ; Kehoe J; Evans J; Kim TW; Farrell NM; White CS; Weinstein ZM; Walley AY
Drug Alcohol Depend; 2022 Jul; 236():109497. PubMed ID: 35607834
[TBL] [Abstract][Full Text] [Related]
9. In-Hospital Methadone Enrollment: a Novel Program to Facilitate Linkage from the Hospital to the Opioid Treatment Program for Vulnerable Patients with Opioid Use Disorder.
Calcaterra SL; Saunders S; Grimm E; Maki-Gianani E; Keniston A; Wold A; Bonaguidi A
J Gen Intern Med; 2024 Feb; 39(3):385-392. PubMed ID: 37715094
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Linkage to an Opioid Treatment Program and Methadone Treatment Retention following Hospital Discharge in a Safety-Net Setting.
Tierney HR; Takimoto SW; Azari S; Steiger S; Martin M
Subst Use Misuse; 2023; 58(9):1172-1176. PubMed ID: 37194561
[No Abstract] [Full Text] [Related]
11. Feasibility of Web-Based Single-Session Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Protocol for a Single-Arm Trial.
Klein MR; Darnall BD; You DS
JMIR Res Protoc; 2024 Jun; 13():e53784. PubMed ID: 38843513
[TBL] [Abstract][Full Text] [Related]
12. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
Saulle R; Vecchi S; Gowing L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
[TBL] [Abstract][Full Text] [Related]
13. "Get in and get out, get on with life": Patient and provider perspectives on methadone van implementation for opioid use disorder treatment.
Suen LW; Steiger S; Shapiro B; Castellanos S; Joshi N; Lambdin BH; Knight KR
Int J Drug Policy; 2023 Nov; 121():104214. PubMed ID: 37778132
[TBL] [Abstract][Full Text] [Related]
14. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
[No Abstract] [Full Text] [Related]
15. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic.
Hallgren KA; Darnton J; Soth S; Blalock KL; Michaels A; Grekin P; Saxon AJ; Woolworth S; Tsui JI
J Subst Abuse Treat; 2022 Dec; 143():108896. PubMed ID: 36215911
[TBL] [Abstract][Full Text] [Related]
16. The rising threat of illicit amphetamine-type stimulant use among methadone maintenance treatment patients in East Coast Malaysia: a retrospective observational study.
Ismail H; Ahmad H; Sanef A; Shahabudin W; Reffin N; Chan D; Dawam D; Hanan F; Nordin M; Sahar L; Daud K; Bongsu KT; Syezri F; Mustapa H
Am J Drug Alcohol Abuse; 2023 Jan; 49(1):97-108. PubMed ID: 36786756
[No Abstract] [Full Text] [Related]
17. Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis.
Iloglu S; Joudrey PJ; Wang EA; Thornhill TA; Gonsalves G
Drug Alcohol Depend; 2021 Mar; 220():108534. PubMed ID: 33497963
[TBL] [Abstract][Full Text] [Related]
18. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
Brothers S; Viera A; Heimer R
J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
[TBL] [Abstract][Full Text] [Related]
19. Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy.
Jarrett JB; Bratberg J; Burns AL; Cochran G; DiPaula BA; Legreid Dopp A; Elmes A; Green TC; Hill LG; Homsted F; Hsia SL; Matthews ML; Ghitza UE; Wu LT; Bart G
Subst Abus; 2023 Oct; 44(4):264-276. PubMed ID: 37902032
[TBL] [Abstract][Full Text] [Related]
20. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
Cochran G; Bruneau J; Cox N; Gordon AJ
Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
